Expression of FGFR1 was also observed in SCLC, although correlation with drug sensitivity was not evaluated in these models.4,19 Evaluation of the predictive potential of FGFR1 RNA, FGF ligands or MYC expression for response to FGFR inhibitors will need to be further assessed in relevant preclinical models of lung cancer that encompass SqCC as well as adenocarcinoma, large-cell carcinoma and SCLC using FGFR-specific inhibitors, to provide insights into the full spectrum of lung tumors that may respond to FGFR inhibition. Here, FGFR1 is linked to lung carcinoma.